Effectiveness of ranitidine bismuth citrate and proton pump inhibitor based triple therapies of helicobacter pylori in Turkey

Libyan Journal of Medicine

Volumn 6, Issue 1, 2011, Pages 1-6

  Alkim, Huseyin ^a   Iscan, Mustafa ^b   Oz, Feriha ^b  

^a BAKIRKOY DR SADI KONUK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b Alman Hospital   (Turkey)

Author keywords

Eradication; Esomeprazole; Helicobacter pylori; Lansoprazole; Omeprazole; Pantoprazole; Rabeprazole and ranitidine bismuth citrate

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE BISMUTH CITRATE;

ADULT; ALLERGY; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DIARRHEA; DRUG CHOICE; DRUG EFFICACY; DRUG WITHDRAWAL; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INFECTION CONTROL; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PARESTHESIA; PATIENT COMPLIANCE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; TURKEY (REPUBLIC);

EID: 80053616146     PISSN: 19932820     EISSN: 18196357     Source Type: Journal    
DOI: 10.3402/ljm.v6i0.8412     Document Type: Article

References (32)

1. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002; 347: 1175-86.
2. Malaty HM, Graham DY. Importance of childhood socioeconomic status on the current prevalence of Helicobacter pylori infection. Gut. 1994; 35: 742-5.
3. Us D, Hascelik G. Seroprevalence of Helicobacter pylori infection in an asymptomatic Turkish population. J Infect. 1998; 37: 148-50.
4. Akin L, Tezcan S, Hascelik G, Cakir B. Seroprevalence and some correlates of Helicobacter pylori at adult ages in Gulveren Health District, Ankara, Turkey. Epidemiol Infect. 2004; 132: 847-56.
5. Seyda T, Derya C, Fusun A, Meliha K. The relationship of Helicobacter pylori positivity with age, sex and ABO/Rhesus blood groups in patients with gastrointestinal complaints in Turkey. Helicobacter. 2007; 12: 244-50.
6. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007; 56: 772-81.
7. Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol. 1998; 93: 2330-8.
8. Paoluzi P, Iacopini F, Crispino P, Nardi F, Bella A, Rivera M, et al. 2-week triple therapy for Helicobacter pylori infection is better than 1-week in clinical practice: a large prospective singlecenter randomized study. Helicobacter. 2006; 11: 562-8.
9. Vakil N, Lanza F, Schwartz H, Barth J. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther. 2004; 20: 99-107.
10. Calvet X, Ducons J, Bujanda L, Bory F, Montserrat A, Gisbert JP. Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial. Am J Gastroenterol. 2005; 100: 1696-701.
11. Della Monica P, Lavagna A, Masoero G, Lombardo L, Crocella L, Pera A. Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy. Aliment Pharmacol Ther. 2002; 16: 1269-75.
12. Altintas E, Sezgin O, Ulu O, Aydin O, Camdeviren H. Maastricht II treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pylori. World J Gastroenterol. 2004; 10: 1656-8.
13. Gumurdulu Y, Serin E, Ozer B, Kayaselcuk F, Ozsahin K, Cosar AM, et al. Low eradication rate of Helicobacter pylori with triple 7-14 days and quadruple therapy in Turkey. World J Gastroenterol. 2004; 10: 668-71.
14. Kadayifci A, Buyukhatipoglu H, Cemil Savas M, Simsek I. Eradication of Helicobacter pylori with triple therapy: an epidemiologic analysis of trends in Turkey over 10 years. Clin Ther. 2006; 28: 1960-6.
15. Chiba N, Hunt RH, Thomson AB. Ranitidine bismuth citrate. Can J Gastroenterol. 2001; 15: 389-98.
16. Vakil N, Cutler A. Ten-day triple therapy with ranitidine bismuth citrate, amoxicillin, and clarithromycin in eradicating Helicobacter pylori. Am J Gastroenterol. 1999; 94: 1197-9.
17. Gisbert JP, Gonzalez L, Calvet X. Systematic review and metaanalysis: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics in Helicobacter pylori eradication. Helicobacter. 2005; 10: 157-71.
18. Malfertheiner P, Megraud F, Giguere M, Riviere M. Quadruple therapy with bismuth subcitrate potassium, metronidazole, tetracycline, and omeprazole is superior to triple therapy with omeprazole, amoxicillin, and clarithromycin in the eradication of Helicobacter pylori [abstract]. Gastroenterology. 2010; 138(Suppl 1): 33.
19. Dore MP, Graham DY, Mele R, Marras L, Nieddu S, Manca A, et al. Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection. Am J Gastroenterol. 2002; 97: 857-60.
20. Midolo PD, Lambert JR, Kerr TG, Tee W. In vitro synergy between ranitidine bismuth citrate and tetracycline or clarithromycin against resistant strains of Helicobacter pylori. Eur J Clin Microbiol Infect Dis. 1999; 18: 832-4.
21. O'Connor A, Gisbert JP, McNamara D, O'Morain C. Treatment of Helicobacter pylori infection 2010. Helicobacter. 2010; 15(Suppl 1): 46-52.
22. Aydin A, Onder GF, Akarca US, Tekin F, Tuncyurek M, Musoglu A. The efficacy of two-week therapy with ranitidine bismuth citrate, amoxicillin and clarithromycin on Helicobacter pylori eradication in clarithromycin-resistant and -sensitive cases. Turk J Gastroenterol. 2005; 16: 203-6.
23. Pace F, Pallotta S, Casalini S, Porro GB. A review of rabeprazole in the treatment of acid-related diseases. Ther Clin Risk Manag. 2007; 3: 363-79.
24. Zhao F, Wang J, Yang Y, Wang X, Shi R, Xu Z, et al. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis. Helicobacter. 2008; 13: 532-41.
25. Erah PO, Goddard AF, Barrett DA, Shaw PN, Spiller RC. The stability of amoxicillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother. 1997; 39: 5-12.
26. Vakil N, Megraud F. Eradication therapy for Helicobacter pylori. Gastroenterology. 2007; 133: 985-1001.
27. Sasaki M, Ogasawara N, Utsumi K, Kawamura N, Kamiya T, Kataoka H, et al. Changes in 12-year first-line eradication rate of Helicobacter pylori based on triple therapy with proton pump inhibitor, amoxicillin and clarithromycin. J Clin Biochem Nutr. 2010; 47: 53-8.
28. Murakami K, Sato R, Okimoto T, Nasu M, Fujioka T, Kodama M, et al. Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin. Aliment Pharmacol Ther. 2002; 16: 1933-8.
29. Sugimoto M, Furuta T, Shirai N, Kodaira C, Nishino M, Ikuma M, et al. Evidence that degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter. 2007; 12: 317-23.
30. Kuwayama H, Asaka M, Sugiyama T, Fukuda Y, Aoyama N, Hirai Y, et al. Japan Rabeprazole Study Group. Rabeprazolebased eradication therapy for Helicobacter pylori: a large-scale study in Japan. Aliment Pharmacol Ther. 2007; 25: 1105-13.
31. Sokmen HM, Demirsoy H, Karaca C, Kesici B, Ozdil K, Ersoy O, et al. Comparison of rabeprazole and ranitidine bismuth citrate with triple combination of amoxicillin, clarithromycin and metronidazole in the eradication of Helicobacter pylori. J Clin Sci Doctor. 2005; 11: 245-9.
32. Aydin A, Oruc N, Turan I, Ozutemiz O, Tuncyurek M, Musoglu A. The modified sequential treatment regimen containing levofloxacin for Helicobacter pylori eradication in Turkey. Helicobacter. 2009; 14: 520-4.